Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer

NCT03699956 is registered in ClinicalTrials.gov with EpicentRx, Inc. as lead sponsor.

NCT NCT03699956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03699956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer
Lead sponsor
EpicentRx, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
December 24, 2018
Completion date
March 1, 2024
Enrollment
18 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, small cell lung